Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : generics boss quits amid conjecture over business's future

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/14/2019 | 03:57am EDT
FILE PHOTO: Richard Francis talks during an interview with Reuters in Basel

ZURICH (Reuters) - Novartis's generics chief is quitting after the Swiss drugmaker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spin-off or sale.

Richard Francis, Sandoz's boss since 2014, is stepping down, Novartis Chief Executive Vas Narasimhan said on Thursday, adding "Richard has decided that for personal reasons he cannot commit to stay with Sandoz until the transformation is completed".

Francesco Balestrieri, head of Sandoz's Europe region, will become interim CEO to oversee what Narasimhan called "a multi-year transformation program" in which Sandoz re-focuses on biosimilars -- copies of patent-expired biological drugs made by rivals -- and hard-to-make generics like insulin.

Balestrieri, at Novartis for 25 years, assumes control over a division with nearly $10 billion in annual sales.

Sandoz last year sold a U.S. pills and dermatology portfolio to India's Aurobindo and embarked on a "de-integration" of Francis's division from the rest of Novartis, a process Narasimhan said will stretch into 2020 and clear the way for talks about the business's future.

Narasimhan has been remaking Novartis by buying speciality treatments like nuclear medicine for cancer and gene therapy, while jettisoning an over-the-counter drugs business and eye surgery-and-contact lens division Alcon, due to be spun off as early as next month.

The departure of Francis, a British citizen, does nothing to quiet conjecture about Sandoz's future within Novartis, analysts said.

"We see our assumption confirmed that in the next 12 to 18 months a definitive decision may come about whether the generic unit will remain within Novartis," said Zuercher Kantonalbank analyst Michael Nawrath.

"Even though the Novartis chairman said recently Sandoz isn't for sale for now, a spin-off like they're doing with Alcon would align with the strategy of becoming a focused, pure-play drugmaker."

(Reporting by John Miller,; Editing by Michael Shields)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
11:31aNOVARTIS : CEO says data quality, lagging innovation crimp China M&A
RE
11:30aNOVARTIS : CEO says data quality, lagging innovation crimp China M&A
RE
09:22aNOVARTIS : CEO sees chance to accelerate profit margin target
RE
01:16aNOVARTIS : highlights company transformation, catalyst-rich pipeline, and strong..
GL
05/22NOVARTIS : phase II data for new inhaled combination treatment (QVM149) demonstr..
GL
05/17NOVARTIS : Five nonprofit organizations to receive up to $250,000 through Novart..
AQ
05/16NOVARTIS : data at ASCO and EHA demonstrate novel approaches to reimagining medi..
GL
05/15NOVARTIS INTERNATIONAL AG : SOLAR-1 NEJM Publication
PU
05/15UPDATE1 : Japan health insurance to cover new leukemia therapy worth 33 mil. yen
AQ
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
More news
Financials ($)
Sales 2019 46 834 M
EBIT 2019 12 446 M
Net income 2019 8 570 M
Debt 2019 15 394 M
Yield 2019 3,49%
P/E ratio 2019 20,75
P/E ratio 2020 19,00
EV / Sales 2019 4,82x
EV / Sales 2020 4,58x
Capitalization 210 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 89,6 $
Spread / Average Target 7,5%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS13.31%210 460
JOHNSON & JOHNSON7.03%368 416
PFIZER-4.54%233 461
ROCHE HOLDING LTD.9.84%228 186
MERCK AND COMPANY5.98%208 495
ABBVIE-11.50%120 617